Drugs / selurampanel
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01649050 | Oct 2016 → Mar 2018 | — | Novartis Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 2 | NCT01617941 | May → Nov 2016 | — | Novartis Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 2 | NCT01338805 | Jun 2011 → Jul 2012 | focal epilepsy | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01167335 | Aug → Nov 2010 | focal epilepsy | Novartis | Withdrawn | No outcome recorded |
| Phase 2 | NCT01147003 | Jun 2010 → Sep 2011 | focal epilepsy | Novartis | Completed | No outcome recorded |
| Phase 2 | NCT00892203 | Apr 2009 → Aug 2010 | migraine disorder | Novartis | Completed | No outcome recorded |
| Phase 2 | NCT00887861 | Mar 2009 → Aug 2010 | epilepsy | Novartis | Completed | No outcome recorded |
| Phase 2 | NCT00784212 | Oct 2008 → Sep 2010 | photosensitive epilepsy | Novartis Pharmaceuticals | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02150213 Background | Aug 2014 → Sep 2015 | adrenal cortex adenoma, uterine corpus endometrial stromal sarcoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | selurampanel | “Examine the efficacy of a competitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)/kainate glutamate receptor antagonist, selurampanel (BGG492), in the human...” PMID 25963722 ↗ May 2015 |
| Known as | BGG492 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00892203 ↗ |
| Action | Inhibit | “competitive AMPA/kainate receptor antagonist” PMID 25963722 ↗ May 2015 |
| Modality | Small molecule | — CHEMBL3545042 ↗ |
| Route | Oral | “single oral BGG492 doses” PMID 25963722 ↗ May 2015 |